Camurus AB

CAMX

Equity

ISIN SE0007692850 / Valor 30510553

NASDAQ Nordic Exchange Stockholm, Equities (2024-09-16)

SEK 672.00-2.11%

Camurus AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Camurus AB is a Swedish pharmaceutical company focused on developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases. The company's proprietary FluidCrystal® drug delivery technologies and extensive R&D expertise are utilized to create new medicinal products with best-in-class potential. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases, which are developed both in-house and in collaboration with international pharmaceutical companies. With headquarters in Lund, Sweden, and regional offices in Cambridge, UK, Mainz, Germany, and Sydney, Australia, Camurus has nearly 200 employees and is listed on Nasdaq Stockholm under the ticker "CAMX."

Summarized from source with an LLMView SourceSector: Healthcare

Q4 Revenue Growth

In the fourth quarter of 2023, Camurus AB reported a significant increase in total revenues, amounting to SEK 375 million, up 40% from SEK 268 million in the same quarter of the previous year. Product sales also saw a substantial rise, reaching SEK 366 million, marking a 37% increase from SEK 267 million.

Operating Results

Camurus AB experienced a downturn in its operating results for the fourth quarter of 2023, recording an operating loss of SEK -29 million compared to a profit of SEK 19 million in the corresponding quarter of the previous year. This decrease included SEK 51 million in social security costs accrued due to increases in employee long-term incentive programs, influenced by the rise in share value during the quarter.

Cash Position

The company's cash reserves significantly strengthened, with cash at the end of the quarter standing at SEK 1,190 million, up by 110% from SEK 566 million at the end of the same quarter the previous year.

Annual Financial Performance

For the full year of 2023, Camurus AB reported total revenues of SEK 1,717 million, an 80% increase from SEK 956 million in 2022. The annual product sales rose by 39% to SEK 1,299 million from SEK 935 million, reflecting strong year-round performance.

Outlook and Developments

Camurus AB raised its revenue and profit before tax guidance for the full year 2023 in October, reflecting confidence in continued financial growth. Additionally, significant advancements in their product pipeline were noted, including the submission of a New Drug Application for Oclaiz™ (CAM2029) for the treatment of acromegaly to the US FDA.

Summarized from source with an LLMView Source

Key figures

131%1Y

285%3Y

654%5Y

Performance

42.3%1Y

41.4%3Y

43.4%5Y

Volatility